HDAC inhibitors: a 2013–2017 patent survey. (4th May 2018)

• Record Type: Journal Article
• Authors: Faria Freitas, Micaela; Cuendet, Muriel; Bertrand, Philippe
• Is Part Of: Expert opinion on therapeutic patents. Volume 28:Number 5(2018)
• Page Start: 365
• Page End: 381
• Publication Date: 2018-05-04
• Subjects: Epigenetics -- cancer -- histone deacetylases -- inhibitors -- synthesis -- biological data; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2018.1459568
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : Zinc-dependent histone deacetylases (HDAC) inhibitors represent an important class of biologically active compounds with four of them approved by the FDA. A wide range of molecules has been reported for applications in several human diseases.Area covered : This review covers recent efforts in the synthesis and applications of HDAC inhibitors from 2013-2017.Expert opinion : HDAC inhibitors represent an important class of biologically active compounds for single or combination therapies. The current synthetic methodologies are oriented towards selective HDAC isoforms to achieve better therapeutic effects. Among the recent patents available, most of them focus on HDAC6 selective inhibitors. Beside this search for isoform selectivity, the quest for zinc binding groups with better pharmacokinetic properties and high potency against HDACs only motivates medicinal chemists, as well as the design of inhibitors targeting HDACs and at the same time another biological target. If the major applications are for anticancer activity, one can note the emerging applications in neurological or metabolic disorders or for the stimulation of the immune system.